Josh Peterson
Last active: 5/19/2014

Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping.

Schildcrout JS, Denny JC, Bowton E, Gregg W, Pulley JM, Basford MA, Cowan JD, Xu H, Ramirez AH, Crawford DC, Ritchie MD, Peterson JF, Masys DR, Wilke RA, Roden DM
Clin Pharmacol Ther. 2012 92 (2): 235-42

PMID: 22739144 · PMCID: PMC3785311 · DOI:10.1038/clpt.2012.66

Routine integration of genotype data into drug decision making could improve patient safety, particularly if many relevant genetic variants can be assayed simultaneously before prescribing the target drug. The frequency of opportunities for pharmacogenetic prescribing and the potential adverse events (AEs) mitigated are unknown. We examined the frequency with which 56 medications with known outcomes influenced by variant alleles were prescribed in a cohort of 52,942 medical home patients at Vanderbilt University Medical Center (VUMC). Within a 5-year window, we estimated that 64.8% (95% confidence interval (CI): 64.4-65.2%) of individuals were exposed to at least one medication with an established pharmacogenetic association. Using previously published results for six medications with severe, well-characterized, genetically linked AEs, we estimated that 383 events (95% CI, 212-552) could have been prevented with an effective preemptive genotyping program. Our results suggest that multiplexed, preemptive genotyping may represent an efficient alternative approach to current single-use ("reactive") methods and may also improve safety.

MeSH Terms (11)

Adult Aged Drug-Related Side Effects and Adverse Reactions Female Genotype Humans Male Middle Aged Patient Safety Pharmacogenetics Polymorphism, Genetic

Connections (5)

This publication is referenced by other Labnodes entities:

Links